News & Media

A Nanotechnology-Designed, Non-Drug Pain Patch Shows Decreases in Pain Severity, Pain Interference, and Concurrent Medications

December 31, 2020

Interim Results from the PREVENT Clinical Trial Published in International Peer-Reviewed Journal –
Anesthesia and Pain Research

Narragansett, Rhode Island, December 31, 2020 -- Clarity Science LLC, a global international scientific research company, based in Narragansett, Rhode Island, announces the latest results of the Institutional Review Board (IRB)-approved PREVENT: “(Pain Relief: Experience and Validity: Evaluating NanoTechnology)” Study.  The interim study results were published today in the international peer-reviewed Journal, Anesthesia and Pain Research.  Sixty-six patients diagnosed with mild, moderate, or severe pain and arthritic, neuropathic, or musculoskeletal pain were evaluated for changes in their pain severity, pain interference, medication usage, and for any side effects after 30 days of using the Kailo Pain Patch® (Pain Relief Technologies; Sandy, Utah). The topline results of the study showed that the mean Brief Pain Inventory (BPI) Severity score decreased 71% (5.2 to 1.5/10;p< .001) and mean BPI Interference score decreased 67% (4.5 to 1.5/10;p< .001). No side effects were reported while 98% of patients reported “less” or “a lot less” usage of oral medications. 97% of patients were very/extremely satisfied with the patch and preferred the pain-relieving patch to oral medications. Results showed Quality of Life (QoL) improvements in mood, relations with other people, sleep, walking ability, and enjoyment of life. At day 30, 83% of patients reported pain relief within 5 minutes of applying the Kailo Pain Patch®.

 “Modern science has allowed the incorporation of nanotechnology into topical patch systems, minimizing, and in the case of Kailo, eliminating the need for drugs/pharmacological agents. The interim results of this study are incredibly positive, and we look forward to providing the next phase of data that we have collected from patients with mild, moderate or severe pain,” said Jeffrey Gudin, MD, the Principal Investigator for the PREVENT Study who is board certified in pain management, anesthesiology, addiction medicine and palliative care. Dr. Gudin is affiliated with University of Miami, Miller School of Medicine, Department of Anesthesiology and Pain Management, and is an author, researcher, and opinion leader in pain management.

Peter Hurwitz, the President of Clarity Science LLC notes, “Healthcare providers continue to seek out alternative and promising pain management approaches for their patients that do not have the side effects commonly associated with traditionally prescribed pain medications.  We are very pleased to share these positive interim results of the PREVENT Study and look forward to continuing our research efforts that may identify other safe and efficacious pain management solutions that healthcare providers can add to their armamentarium.”

About Clarity Science LLC:
Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, Clarity aspires to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide ( any further detail contact our Business Development Manager, Mackenzie Hastings, at .